MYOV News and Press, Myovant Sciences Ltd. From 08/27/19

BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated today at 8:30 AM ET. The date for Lynn Seely's presentation was incorrectly listed. The complete and corrected release follows: Myovant Sciences (NYSE: ...

BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced its participation ...

Preface Shares of Neurocrine Biosciences ( NBIX ) are up nearly 40% since I published the article , in December 2018, citing my belief that shares of NBIX would see $100 again. At that time, Neurocrine had revealed disappointing data in Tourette's and traded in the low $70s. Since then...

Myovant Sciences (NYSE: MYOV ) completes enrollment in the first of two Phase 3 replicate clinical trials, SPIRIT 2 , evaluating relugolix combo therapy in women with endometriosis-associated pain. More news on: Myovant Sciences Ltd., AbbVie Inc., Healthcare stocks news, Stocks on the m...

- Top-line data for SPIRIT 2 expected in first quarter of 2020 - Company on track to announce top-line results from SPIRIT 1 in second quarter of 2020 BRISBANE, Calif., and BASEL, Switzerland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare ...

Myovant ( MYOV ) announced that it had achieved positive results from the LIBERTY 2 phase III study using a once-daily relugolix combination therapy to treat women with uterine fibroids. The biotech had already met on the primary endpoint for its first phase III study known as LIBERTY 1. T...

Health Catalyst (NASDAQ: HCAT ) initiated with Buy rating and $49 (16% upside) price target at Goldman Sachs. Initiated with Buy rating and $53 price target at SunTrust, Outperform with a $50 a target at Evercore ISI, Outperform with a $55 target at SVB Leerink, Outperform at William Blair a...

Myovant Sciences (NYSE: MYOV ): Q1 GAAP EPS of -$0.89 beats by $0.10 . More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

-Positive results from both Phase 3 LIBERTY trials and bioequivalence study supports submission of NDA for uterine fibroids which is expected by year end 2019 and MAA which is expected by Q1-2020- -Top-line data from Phase 3 HERO trial in advanced prostate cancer expected by year e...

Chiasma (NASDAQ: CHMA ) +21%  as Mycapssa successful in late-stage acromegaly study. More news on: Chiasma, Inc., Realogy Holdings Corp., Diffusion Pharmaceuticals Inc., Stocks on the move, Read more ...